Osphos (clodronate) Injectable for Horses - 60mg/mL, 15 mL
Description: Osphos is a bisphosphonate solution given via intramuscular injection used for the control of clinical signs associated with navicular syndrome in horses. Product: Osphos Injectable Solution For: Horses Generic Name: Clodronate Brand Names: Osphos Drug Class: Bisphosphonate Manufacturer: Dechra Product Description & Form: Osphos 60 mg ml Solution 15 ml: Colorless injectable solution. (NDC 17033 0460 15)Osphos 60 mg ml Solution 15 ml Benefits: Inhibits bone resorption by decreasing the number of active osteoclasts (cells which absorb bone) and inhibiting the formation and dissolution of calcium phosphate crystals in the bone matrix, leading to a decrease in the breakdown of bone. Improves the signs of lameness Each ml contains 60 mg of clodronate Each vial contains 900 mg of clodronate Active Ingredients: Clodronate disodium Inactive Ingredients: Sodium hydroxide, water Usage: Osphos injection should be given to your horse as directed by your veterinarian. Injections are given intramuscularly, divided evenly into three separate injection sites. Suitable injections sights include the pectoral muscles, the center of lower neck, and hind gluteal muscles. Use aseptic techniques when withdrawing each dose to decrease the possibility of post injection bacterial infections. Adequately clean and disinfect the stopper prior to entry with a sterile needle and syringe. Discard unused vial contents, as this is provided as single use vial and does not contain preservative. Discard unused vial contents, as this is provided as single use vial and does not contain preservative. Injectable medications require needles and syringes. Those items are purchased separately. Please ask your veterinarian for a recommendation for the correct needle syringe sizes for your pet.Use only sterile needles syringes and use each needle syringe only once. Dispose the needle syringe immediately in a proper sharps disposal container. Sharps containers are sold separately. Injectable medications require needles and syringes. Those items are purchased separately. Please ask your veterinarian for a recommendation for the correct needle syringe sizes for your pet. Missed Doses: Give the dose as soon as possible. If it is almost time for the next dose, skip the missed dose, and continue with the regular schedule. Do not give 2 doses at once. Side Effects: Most common side effects were signs of discomfort or nervousness, cramping, colic, and or pawing. Drug & Food Interactions: The following drugs can potentially interact with Osphos : aminoglycosides, digoxin, furosemide, phenylbutazone, and tetracyclines. Contact your veterinarian if your pet experiences any unusual reactions when different medications are given together. Make sure to tell your veterinarian what other medication you are giving to your pet. Quite often your veterinarian may prescribe two different medications, and a drug interaction may be anticipated. In this case, your veterinarian may vary the dose and or monitor your pet more closely. Cautions: Keep out of reach of children. Not for human use. If there is no response to initial therapy, the horse should be re evaluated. For horses that initially respond to Osphos but do not maintain clinical improvement for 6 months, Osphos may be re administered at 3 to 6 month intervals based on recurrence of clinical signs. For horses that respond to Osphos and maintain clinical improvements for 6 months, Osphos should be re administered after clinical signs recur. Horses should be monitored for at least 2 hours following administration for signs of colic, agitation, and or nervous system abnormalities. If a horse appears uncomfortable, nervous, or experiences cramping post treatment it is advised to hand walk the horse for 15 minutes until signs resolve. Contact the veterinarian if the horse displays abnormal clinical signs. Osphos should not be used in pregnant or lactating mares, or mares intended for breeding. The safe use of Osphos has not been evaluated in horses less than 4 years of age. Use of Osphos in patients with conditions affecting renal function or mineral or electrolyte homeostasis is not recommended. Allergic reactions to medications may occur. Be sure to inform VetSource and your veterinarian if your pet has any known drug sensitivities or allergies. If your pet experiences an allergic reaction to the medication, signs may include facial swelling, hives, scratching, sudden onset of diarrhea, vomiting, shock, seizures, pale gums, cold limbs, or coma. If your pet displays symptoms of an allergic reaction, call your veterinarian immediately or go to a veterinary emergency clinic. Adverse Reactions: If you are concerned that your pet has experienced an adverse reaction to this medication, please contact the manufacturer Dechra at 866 307 0789 or Vetsource customer service at 877 738 4443. Storage: Store at 77 F in controlled room temperature, excursions permitted between 59 F to 86 F. Keep this medicine out of reach of children. Store in a childproof container. Store this medicine in a cool, dry place at room temperature. Store away from heat and direct sunlight. Do not store this medicine in the bathroom, near the kitchen sink or in damp places. The medicine may break down if exposed to heat or moisture. Sourced directly from the manufacturer or their approved distributor. Guaranteed genuine product backed by the manufacturer. Sourced directly from the manufacturer or their approved distributor. Guaranteed genuine product backed by the manufacturer.View details
Osphos Inj 60mg/mL, 15 ml
DESCRIPTION: Osphos Injection uses Clodronate, which aids in symptomatic relief of navicular syndrome and slows progression of the disease. It doesn't require dilution, and it comes in an easy and ready-to-use vial. Key Benefits: Osphos inhibits bone resorption. It works to bind to calcium phosphate crystals, and it directly affects osteoclast cells. This is useful in inhibiting their formation and dissolution. Formulated For: For horses ages 4 and up. How is Medication Given? Administer intramuscularly at a rate of 1.8 mg per kg of body weight. Maximum dosage rate is 900 mg for each horse (which is one full vial). Total dosage volume should be injected between three separate sites. Any unused contents of the vial should be discarded. This product is preservative-free and comes in a one-use vial. If the animal does not respond to the first treatment, re-evaluation is recommended. If improvement of clinical signs does not last for 6 months, re-administer another dose every 3 to 6 months. depending upon symptom recurrence. If improvement is maintained for a 6-month period, re-administer upon recurrence of clinical signs. What Results Can I Expect? Osphos: Delivers 60 mg of Clodronate in every mL Is the only option for intramuscular administration Is an injectable bisphosphonate solution that helps control the clinical signs associated with navicular syndrome Is a great choice for horses who have been diagnosed (in radiography) to have navicular syndrome-related bony changes Prevents the resorption of bones by exerting a direct effect on osteoclas cells, binding to calcium phosphate crystals, and inhibiting their formation and dissolution What Form Does Medication Come In? Injectable Dose and Administration: Sold in a vial containing 15 mL (60 mg per mL). Possible Side Effects: In field studies, the following side effects were observed within 2 hours: Discomfort Nervousness Cramping Pawing Colic 8 out of 10 affected horses experienced symptom resolution after a 10- to 15-minute hand walk. 1 horse's symptoms resolved without being walked. 1 was treated for colic. The colic-treated horse also had hives, which was resolved with Flunixin and Dexamethasone. Precautions Keep out of reach of children. Storage Recommendations: Store in a cool and dry location. In Case of Overdose: Call your nearest animal hospital. Active Ingredients: Contains the bisphosphonate Clodronic acid in each Osphos injection solution. Main Ingredients: This product contains 15 mg of Clodronic Acid per mL. Clodronic Acid is a bisphosphonate.View details